Form 4 for TXG 10x Genomics, Inc.
Accepted 2023-11-22 00:00:00 ET · period of report 2023-11-20 · accession 0001610717-23-000361 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-22 | 2023-11-20 | TXG | Wilbur James | Chief Commercial Off | S - Sale | $42.09 | -14.7K | 86.8K | -14% | -$619.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-11-20 | S | D | 14,718 | $42.09 | 86,806 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $42.05 to $42.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F2) Includes 271 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 14, 2023. |